ID   SK-N-AS
AC   CVCL_1700
SY   SKN-AS; SKNAS
DR   BTO; BTO:0002827
DR   CLO; CLO_0009051
DR   EFO; EFO_0002859
DR   CLDB; cl4330
DR   CLDB; cl4331
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-6654
DR   ATCC; CRL-2137
DR   BioGRID_ORCS_Cell_line; 376
DR   BioSample; SAMN03473210
DR   BioSample; SAMN10987940
DR   cancercelllines; CVCL_1700
DR   Cell_Model_Passport; SIDM01101
DR   CGH-DB; 61-1
DR   CGH-DB; 9098-4
DR   ChEMBL-Cells; CHEMBL3308785
DR   ChEMBL-Targets; CHEMBL1075578
DR   Cosmic; 724828
DR   Cosmic; 848935
DR   Cosmic; 930074
DR   Cosmic; 1019941
DR   Cosmic; 1109104
DR   Cosmic; 1162002
DR   Cosmic; 1167418
DR   Cosmic; 1518070
DR   Cosmic; 1526646
DR   Cosmic; 1543772
DR   Cosmic; 2058112
DR   Cosmic; 2239472
DR   Cosmic; 2393642
DR   Cosmic; 2485950
DR   Cosmic-CLP; 724828
DR   DepMap; ACH-000260
DR   ECACC; 94092302
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 724828
DR   GEO; GSM563352
DR   GEO; GSM692855
DR   GEO; GSM887592
DR   GEO; GSM888675
DR   GEO; GSM1670449
DR   GEO; GSM2371254
DR   GEO; GSM2394379
DR   GEO; GSM4104591
DR   GEO; GSM4104592
DR   GEO; GSM4104635
DR   GEO; GSM4104636
DR   GEO; GSM4105338
DR   GEO; GSM4105339
DR   GEO; GSM4105340
DR   GEO; GSM4105341
DR   GEO; GSM4105342
DR   IARC_TP53; 23597
DR   ICLC; HTL95026
DR   IGRhCellID; SKNAS
DR   LiGeA; CCLE_394
DR   LINCS_LDP; LCL-1969
DR   Lonza; 447
DR   Lonza; 1617
DR   MetaboLights; MTBLS541
DR   PharmacoDB; SKNAS_1404_2019
DR   PRIDE; PXD010745
DR   PRIDE; PXD011187
DR   PRIDE; PXD023088
DR   PRIDE; PXD024551
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1700
DR   PubChem_Cell_line; CVCL_1700
DR   Wikidata; Q54954411
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   DOI=10.1159/000407025;
RX   PubMed=2987426;
RX   PubMed=6610792;
RX   PubMed=7838528;
RX   PubMed=9283597;
RX   PubMed=11550280;
RX   PubMed=12068308;
RX   PubMed=12702577;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=17506115;
RX   PubMed=18082704;
RX   PubMed=18534018;
RX   PubMed=18724359;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20655465;
RX   PubMed=22213050;
RX   PubMed=22460905;
RX   PubMed=23202128;
RX   PubMed=24466371;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28192521;
RX   PubMed=28350380;
RX   PubMed=30459281;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=33921066;
RX   PubMed=35839778;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=SK-N-AS
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-509.html
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Population: Caucasian.
CC   HLA typing: A*24:02,26:01; B*14:01,40:01; C*03:04,08:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Chromatin accessibility by ATAC-seq.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K27me3 ChIP-seq epigenome analysis.
CC   Omics: H3K4me1 ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.49%; Native American=0%; East Asian, North=2.41%; East Asian, South=0%; South Asian=2.58%; European, North=53.12%; European, South=40.39% (PubMed=30894373).
CC   Misspelling: SK-NA-S; PubMed=15892104.
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): ATCC; Cosmic-CLP; ECACC; PubMed=25877200; PubMed=28192521
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9
ST   D16S539: 14
ST   D18S51: 14,15
ST   D21S11: 32.2,33.2
ST   D3S1358: 14
ST   D5S818: 11,12
ST   D7S820: 11,13
ST   D8S1179: 13,14
ST   FGA: 20,22
ST   Penta D: 9
ST   Penta E: 7,14
ST   TH01: 9.3
ST   TPOX: 11,12
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   6Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 43
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   DOI=10.1159/000407025;
RA   Helson L., Verma M., Helson C.;
RT   "Vitamin E and human neuroblastoma.";
RL   (In) Modulation and mediation of cancer by vitamins; Meyskens F.L., Prasad K.N. (eds.); pp.258-265; Karger; Basel (1983).
//
RX   PubMed=2987426; DOI=10.1007/BF00165170;
RA   Helson L., Helson C.;
RT   "Human neuroblastoma cells and 13-cis-retinoic acid.";
RL   J. Neurooncol. 3:39-41(1985).
//
RX   PubMed=6610792; DOI=10.1093/jnci/73.1.51;
RA   Sugimoto T., Tatsumi E., Kemshead J.T., Helson L., Green A.A.,
RA   Minowada J.;
RT   "Determination of cell surface membrane antigens common to both human
RT   neuroblastoma and leukemia-lymphoma cell lines by a panel of 38
RT   monoclonal antibodies.";
RL   J. Natl. Cancer Inst. 73:51-57(1984).
//
RX   PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
RX   PubMed=9283597; DOI=10.1016/S0165-4608(96)00362-7;
RA   Van Roy N., Jauch A., Van Gele M., Laureys G., Versteeg R.,
RA   De Paepe A., Cremer T., Speleman F.;
RT   "Comparative genomic hybridization analysis of human neuroblastomas:
RT   detection of distal 1p deletions and further molecular genetic
RT   characterization of neuroblastoma cell lines.";
RL   Cancer Genet. Cytogenet. 97:135-142(1997).
//
RX   PubMed=11550280; DOI=10.1002/gcc.1174;
RA   Van Roy N., Van Limbergen H., Vandesompele J., Van Gele M., Poppe B.,
RA   Salwen H.R., Laureys G., Manoel N., De Paepe A., Speleman F.;
RT   "Combined M-FISH and CGH analysis allows comprehensive description of
RT   genetic alterations in neuroblastoma cell lines.";
RL   Genes Chromosomes Cancer 32:126-135(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=17506115; DOI=10.1002/nbm.1181;
RA   Peet A.C., McConville C.M., Wilson M.P., Levine B.A., Reed M., Dyer S.A.,
RA   Edwards E.C., Strachan M.C., McMullan D.J., Wilkes T.M., Grundy R.G.;
RT   "1H MRS identifies specific metabolite profiles associated with
RT   MYCN-amplified and non-amplified tumour subtypes of neuroblastoma cell
RT   lines.";
RL   NMR Biomed. 20:692-700(2007).
//
RX   PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026;
RA   Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M.,
RA   Hayashi Y.;
RT   "Identification of side population cells (stem-like cell population)
RT   in pediatric solid tumor cell lines.";
RL   J. Pediatr. Surg. 42:2040-2045(2007).
//
RX   PubMed=18534018; DOI=10.1186/1476-4598-7-50;
RA   Combaret V., Boyault S., Iacono I., Brejon S., Rousseau R.,
RA   Puisieux A.;
RT   "Effect of bortezomib on human neuroblastoma: analysis of molecular
RT   mechanisms involved in cytotoxicity.";
RL   Mol. Cancer 7:50.1-50.12(2008).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20655465; DOI=10.1016/j.cell.2010.06.004;
RA   Holzel M., Huang S.-D., Koster J., Ora I., Lakeman A., Caron H.N.,
RA   Nijkamp W., Xie J., Callens T., Asgharzadeh S., Seeger R.C.,
RA   Messiaen L.M., Versteeg R., Bernards R.;
RT   "NF1 is a tumor suppressor in neuroblastoma that determines retinoic
RT   acid response and disease outcome.";
RL   Cell 142:218-229(2010).
//
RX   PubMed=22213050; DOI=10.1002/ijc.27415;
RA   Gawecka J.E., Geerts D., Koster J., Caliva M.J., Sulzmaier F.J.,
RA   Opoku-Ansah J., Wada R.K., Bachmann A.S., Ramos J.W.;
RT   "PEA15 impairs cell migration and correlates with clinical features
RT   predicting good prognosis in neuroblastoma.";
RL   Int. J. Cancer 131:1556-1568(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24466371; DOI=10.1593/tlo.13544;
RA   Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J.,
RA   Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A.,
RA   Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.;
RT   "Testing of SNS-032 in a panel of human neuroblastoma cell lines with
RT   acquired resistance to a broad range of drugs.";
RL   Transl. Oncol. 6:685-696(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28192521; DOI=10.1371/journal.pone.0172140;
RA   Saintas E., Abrahams L., Ahmad G.T., Ajakaiye A.-O.M., AlHumaidi A.S.H.A.M.,
RA   Ashmore-Harris C., Clark I., Dura U.K., Fixmer C.N., Ike-Morris C.,
RA   Mato Prado M., McCullough D., Mishra S., Scholer K.M.U., Timur H.,
RA   Williamson M.D.C., Alatsatianos M., Bahsoun B., Blackburn E.,
RA   Hogwood C.E., Lithgow P.E., Rowe M., Yiangou L., Rothweiler F.,
RA   Cinatl J. Jr., Zehner R., Baines A.J., Garrett M.D., Gourlay C.W.,
RA   Griffin D.K., Gullick W.J., Hargreaves E., Howard M.J., Lloyd D.R.,
RA   Rossman J.S., Smales C.M., Tsaousis A.D., von der Haar T., Wass M.N.,
RA   Michaelis M.;
RT   "Acquired resistance to oxaliplatin is not directly associated with
RT   increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly
RT   established oxaliplatin-resistant sub-line of the neuroblastoma cell
RT   line SK-N-AS.";
RL   PLoS ONE 12:E0172140-E0172140(2017).
//
RX   PubMed=28350380; DOI=10.1038/sdata.2017.33;
RA   Harenza J.L., Diamond M.A., Adams R.N., Song M.M., Davidson H.L.,
RA   Hart L.S., Dent M.H., Fortina P., Reynolds C.P., Maris J.M.;
RT   "Transcriptomic profiling of 39 commonly-used neuroblastoma cell
RT   lines.";
RL   Sci. Data 4:170033-170033(2017).
//
RX   PubMed=30459281; DOI=10.1126/scisignal.aar5680;
RA   Van den Eynden J., Umapathy G., Ashouri A., Cervantes-Madrid D.,
RA   Szydzik J., Ruuth K., Koster J., Larsson E., Guan J.-K., Palmer R.H.,
RA   Hallberg B.;
RT   "Phosphoproteome and gene expression profiling of ALK inhibition in
RT   neuroblastoma cell lines reveals conserved oncogenic pathways.";
RL   Sci. Signal. 11:eaar5680.1-eaar5680.16(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=33921066; DOI=10.3390/cancers13081909;
RA   Siaw J.T., Gabre J.L., Uckun E., Vigny M., Zhang W.-C.,
RA   Van den Eynden J., Hallberg B., Palmer R.H., Guan J.-K.;
RT   "Loss of RET promotes mesenchymal identity in neuroblastoma cells.";
RL   Cancers (Basel) 13:1909.1-1909.25(2021).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//